151 related articles for article (PubMed ID: 8526739)
1. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.
Sato F; Hagiwara Y; Kawase Y
Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats.
Adachi J; Gomez M; Smith CC; Sternberg EM
Arch Toxicol; 1995; 69(4):266-70. PubMed ID: 7755488
[TBL] [Abstract][Full Text] [Related]
3. Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.
Adachi J; Mio T; Ueno Y; Naito T; Nishimura A; Fujiwara S; Sumino K; Tatsuno Y
Arch Toxicol; 1994; 68(8):500-5. PubMed ID: 7802590
[TBL] [Abstract][Full Text] [Related]
4. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
[TBL] [Abstract][Full Text] [Related]
5. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
[TBL] [Abstract][Full Text] [Related]
6. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
Martínez-Cabot A; Messeguer A
Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and analysis of contaminants in ems-related tryptophan.
Steinhart H; van Wickern B; Meyer K; Simat T
Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
[No Abstract] [Full Text] [Related]
8. Effect of 3-phenylamino-L-alanine on tryptophan binding to rat hepatic nuclear envelopes.
Sidransky H; Verney E; Cosgrove JW; Latham PS
Toxicology; 1994 Jan; 86(1-2):135-45. PubMed ID: 8134920
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia-myalgia syndrome.
Adachi J; Ueno Y; Tatsuno Y; Gomez M; Smith CC; Sternberg EM
Adv Exp Med Biol; 1996; 398():365-70. PubMed ID: 8906290
[No Abstract] [Full Text] [Related]
10. Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan.
Müller B; Pacholski C; Simat T; Steinhart H
Adv Exp Med Biol; 1999; 467():481-6. PubMed ID: 10721091
[TBL] [Abstract][Full Text] [Related]
11. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
[TBL] [Abstract][Full Text] [Related]
12. Animal models of the eosinophilia-myalgia syndrome.
Clauw DJ
J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale.
Mayeno AN; Gleich GJ
Trends Biotechnol; 1994 Sep; 12(9):346-52. PubMed ID: 7765187
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
[TBL] [Abstract][Full Text] [Related]
15. Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome.
Hill RH; Caudill SP; Philen RM; Bailey SL; Flanders WD; Driskell WJ; Kamb ML; Needham LL; Sampson EJ
Arch Environ Contam Toxicol; 1993 Jul; 25(1):134-42. PubMed ID: 8346973
[TBL] [Abstract][Full Text] [Related]
16. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome.
Milburn DS; Myers CW
DICP; 1991 Nov; 25(11):1259-62. PubMed ID: 1763543
[TBL] [Abstract][Full Text] [Related]
17. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
Zangrilli JG; Mayeno AN; Vining V; Varga J
Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome.
Daniels SR; Hudson JI; Horwitz RI
J Clin Epidemiol; 1995 Dec; 48(12):1413-27; discussion 1429-40. PubMed ID: 8543957
[TBL] [Abstract][Full Text] [Related]
19. 3-anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples.
Goda Y; Suzuki J; Maitani T; Yoshihira K; Takeda M; Uchiyama M
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2236-8. PubMed ID: 1423790
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.
Adachi J; Naito T; Ueno Y; Ogawa Y; Ninomiya I; Tatsuno Y
Arch Toxicol; 1993; 67(4):284-9. PubMed ID: 8517785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
